Ginger

ApprovedSmall molecule

UUniversity of Rochester

Ginger is one of 187 small molecule programs targeting Alcoholic Fatty Liver Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

186

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alcoholic Fatty Liver DiseaseActive, not recruiting

VertigoActive, not recruiting

Chemotherapy-Induced Nausea and VomitingActive, not recruiting

Nausea and VomitingActive, not recruiting

Back PainActive, not recruiting

Cesarean SectionActive, not recruiting

Alcoholic Fatty Liver DiseasePhase 1

Active, not recruiting

VertigoApproved

Active, not recruiting

Chemotherapy-Induced Nausea and VomitingPhase 2

Active, not recruiting

Nausea and VomitingPhase 2/Phase 3

Active, not recruiting

Back PainApproved

Active, not recruiting

Cesarean SectionApproved

Active, not recruiting

Competition

Competitive Landscape

230 competitors in Cesarean Section

#DrugCompanyPhaseTrials

Ginger

UUniversity of Rochester

Approved

1 2

Marcaine

IInnocoll

Preclinical

21 3

Pitocin

RRetrophin

Preclinical

16 4

Naropin

FFresenius Kabi Oncology Ltd.

Preclinical

12 5

Neo-Synephrine

EExela Pharma Sciences, LLC.

Preclinical

11 6

Proamatine

Takeda

Preclinical

1 7

Ancef

BBaxter Healthcare Corporation

Preclinical

3 8

Nubain

AAultman Health Foundation

Preclinical

3 9

Intrathecal Morphine

Pacira Pharmaceuticals, Inc

Preclinical

5 10

AMPHADASE

AAmphastar Pharmaceuticals, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Nausea and Vomiting

NCT07190495

Q1 2028

Phase 2Recruiting

Pain

NCT06817018

Clinical

Trials by Indication[1]

Nausea and vomiting3 trials

Ginger Control of Chemotherapy Induced Nausea and Vomiting

Completed·NNational Center for Complementary and Integrative Health (NCCIH)·Phase 2·NCT00065221·180 enrolled

Efficacy of Ginger on Intraoperative and Postoperative Nausea and Vomiting in Elective Cesarean Section Patients

Completed·JJoel Yarmush·Phase 2/3·NCT01733212·239 enrolled

Ginger to Prevent Nausea and Vomiting After Laparoscopic Cholecystectomy

Recruiting·UUniversity Tunis El Manar·Phase 4·NCT07190495·102 enrolled

Cesarean Section1 trial

Efficacy of Ginger in the Prevention of Abdominal Distention in Post Cesarean Section Patient

Completed·—·Phase 4·NCT02809027·178 enrolled

Vertigo1 trial

Evaluation of Aminobutyric Acid, Glutamic Acid, Calcium, Thiamine, Pyridoxine and Cyanocobalamin as Therapy for Vertigo

Completed·FFundação Educacional Serra dos Órgãos·Phase 4·NCT05221892·334 enrolled

Efficacy1 trial

Efficacy of Ginger Extract (Compare Between the Ginger Preparation of Ancient Concept of Thai Traditional Practitioner, Standard Drug and Placebo) by Using Pain Score to Evaluate After Pain of Three Groups of First Normal Postpartum Women.

Completed·TThammasat University·Phase 1/2·NCT03617900·99 enrolled

Chemotherapy-induced nausea and vomiting1 trial

Efficacy of Ginger as an Adjunctive Prophylaxis for Chemotherapy-induced Nausea and Vomiting

Completed·MMahidol University·Phase 2·NCT02390648·34 enrolled

6 more indications

Chemotherapy1 trial

Aromatherapy for Chemotherapy-induced Symptoms

Terminated·UUniversity of Rochester·Phase 1·NCT02670941·31 enrolled

Pain1 trial

Ginger Root Extract for Sciatic Pain Individuals

Recruiting·LLeslie Shen·Phase 2·NCT06817018·80 enrolled

Back pain1 trial

Glucosamine Sulphate, Ginger, Ginger-Avocado-Soya and Ginger-Ibuprofen for Chronic Back Pain

Completed·FFerrosan AS·Phase 4·NCT00317655·175 enrolled

Pain Management1 trial

the Efficacy of Ginger Powder as an Analgesic for Intraoperative and Post- Endodontic Pain Management

Not yet recruiting·—·Phase 3·NCT06439212·50 enrolled

Dental Pain1 trial

Anti Inflammatory and Analgesic Effect of Ginger Powder in Dental Pain Model

Unknown status·QQazvin University Of Medical Sciences·Phase 2·NCT01429935·60 enrolled

Alcoholic Fatty Liver Disease1 trial

Effects of Ginger on Nonalcoholic Fatty Liver Disease in T2DM

Completed·SShiraz University of Medical Sciences·Phase 1·NCT02289235·76 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Ginger. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ginger compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ginger. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Rochester company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of Rochester

Ginger

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2028

Trials by Indication[1]

Nausea and vomiting3 trials

Cesarean Section1 trial

Vertigo1 trial

Efficacy1 trial

Chemotherapy-induced nausea and vomiting1 trial

Chemotherapy1 trial

Pain1 trial

Back pain1 trial

Pain Management1 trial

Dental Pain1 trial

Alcoholic Fatty Liver Disease1 trial

References

Drug Info

Quick Facts

Related News